Replies to post #3540 on CardioVascular BioTherapeutics (fka CVBT)

[apdp]

I agree and that was the point I was trying to make. To value the patents would be speculative. The value is there IMP once trials commence and the science is proven. Does not say at some point major pharma steps in and buys or partners with Venturis.